

[Investor's Overview](#) | [Corporate Governance](#) | [Stock Quote](#) | [Stock Chart](#) | [News Releases](#) | [Analyst Coverage](#) | [Investment Calculator](#) | [Investor FAQ](#) | [Annual Report](#) | [SEC Filings](#) | [Senior Executive Transactions](#) | [Calendar](#) | [Fundamentals](#) | [Information Request](#) | [Audio Archives](#) | [Presentations](#) | [E-Mail Alerts](#) | [Home](#)

INVESTOR RELATIONS

Senior Executive Stock Transactions

The Medicines Company believes it is important that investors understand the intentions and motivations of our senior executives regarding purchases and sales of the Company's common stock. To that end, the Company is providing the comments below, which are posted following stock ownership-related SEC filings by key executives.

This page contains pertinent information regarding updates to stock transactions by senior executives of The Medicines Company and is intended to supplement information contained in the executives' filings with the SEC. A link to actual SEC filings is provided above.

Following are some of the stock ownership-related terms that may be discussed on this page:

10b5-1 Plan: *prearranged trading plan:* allows corporate insiders to establish prearranged plans to sell or purchase a certain number or dollar amount of shares of company stock over a predetermined period of time. 10b5-1 plans may be adopted to, among other things, allay concerns about initiating stock transactions while in possession of material nonpublic information.

Form 144: *proposed sale:* provides the number of shares of Company common stock that the officer intends to sell during the three-month period beginning on the date on which the Form 144 is filed.

Form 4: *transaction has been completed:* discloses an actual sale or purchase of stock by an insider by reporting a change in his or her beneficial ownership of the Company's securities.

The Medicines Company provides this information as background only and, in doing so, does not undertake to update the postings, nor provide postings for every insider stock transaction. Information contained in this Investor Relations section of our Web site is for informational purposes only, and this information shall not constitute an offer to sell the securities by the Company or any such officer in any jurisdiction.

We hope that this information provides additional transparency to the actions of our senior executives and affirms the trust and confidence that investors have placed in The Medicines Company.

August 23, 2004 — Clive Meanwell, Chairman, President and CEO, entered into stock transaction known as a pre-paid variable forward sales contract with a brokerage firm. Commenting on the transaction, Dr. Meanwell stated: "I am pleased to again participate in the present and anticipated future growth of The Medicines Company. This is my first opportunity for a stock transaction in 2004, and the forward sales contract reflects that I expect the future prospects of the Company to be stronger than ever. The initial proceeds of the transaction will allow me to personally invest in current family projects."

December 29, 2003 — Dave Stack, Director, President and CEO filed a Form 144 with respect to trades under the Rule 10b5-1 trading plan. Commenting on the transaction, Mr. Stack stated: "This filing prepares for execution of my annual 10b5-1 trading plan. I have renewed the program that was established last year with a similar schedule for 2004."

June 18, 2003 — Clive Meanwell, Executive Chairman, entered into stock transaction known as a pre-paid variable forward sales contract with a brokerage firm. Commenting on the transaction, Dr. Meanwell stated: "I continue to be delighted with the progress of The Medicines Company and look forward to taking the opportunity to participate further in its success. In the last six months, my confidence in the future growth of MDCO continues to increase. As this transaction implies, I am confident that the future prospects of the Company are strong."

November 26, 2002 — Clive Meanwell, Executive Chairman, entered into stock transaction known as a pre-paid variable forward sales contract with a brokerage firm. Commenting on the transaction, Dr. Meanwell stated: "As a founder, I am delighted with the progress of The Medicines Company and look forward to taking the opportunity to participate further in its success. The forward sales, which apply to less than one-third of my current MDCCO holdings, will be made on stock I acquired as a founder, as well as some I purchased as the Company has developed. I am confident that the future prospects of the Company are strong."

November 22, 2002 — Dave Stack, Director, President and CEO filed a Form 144 with respect to trades under a Rule 10b5-1 trading plan. Commenting on the transaction, Mr. Stack stated: "This transaction is in line with my 10b5-1 trading plan. The planned sales were established following the opening of a trading window after the presentation of REPLACE-2 data."